488 Results for "

prepartum transition dairy cows

" in MedChemExpress (MCE) Product Catalog:
Products (488)

488 Results for "prepartum transition dairy cows" in MCE Product Catalog:

907
907 Publications Verification
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
loading...
    loading...
496
496 Cited Publications
Cat. No.: HY-108232
CAS No.: 1032349-77-1
Purity:  99.72%
MK-2206 is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .
loading...
    loading...
496
496 Cited Publications
Cat. No.: HY-10358
CAS No.: 1032350-13-2
Purity:  99.94%
Synonyms: MK-2206 (2HCl)
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .
loading...
    loading...
136
136 Cited Publications
Cat. No.: HY-15244
CAS No.: 1217486-61-7
Purity:  99.88%
Synonyms: BYL-719
Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
136
136 Cited Publications
Cat. No.: HY-15244A
CAS No.: 1584128-91-5
Synonyms: BYL-719 hydrochloride
Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
loading...
    loading...
80
80 Cited Publications
Cat. No.: HY-N0488A
CAS No.: 57-22-7
Synonyms: Leurocristine; NSC-67574; 22-Oxovincaleukoblastine
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .
loading...
    loading...
80
80 Cited Publications
Cat. No.: HY-N0488
CAS No.: 2068-78-2
Synonyms: Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) sulfate is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-13817
CAS No.: 314245-33-5
Purity:  99.30%
IU1 is a selective, reversible USP14 inhibitor with an IC50 of 4-5 μM. IU1 binds USP14’s catalytic cleft to block deubiquitinase activity. IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux, reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells. IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis, and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance. IU1 can be used for the research of Alzheimer’s disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative disease .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0025
CAS No.: 143205-42-9
Synonyms: (Melle-4)cyclosporin; SDZ NIM811
NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-100852
CAS No.: 792957-74-5
Purity:  ≥98.0%
Research Areas:  

Cancer

ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-16307
CAS No.: 261365-11-1
Target:  

FBPase

Research Areas:  

Metabolic Disease Cancer

MB05032 is a fructose-1,6-bisphosphatase (FBP1/FBPase) inhibitor with an IC50 value of 16 nM. MB05032 blocks FBP1-mediated glycolysis inhibition in NK cells, restores NK cell glucose uptake, lactate production, degranulation, perforin production, and cytotoxicity against gastric cancer cells. MB05032 elevates ATP/ADP ratios, increases glucose utilization, and enhances insulin secretion in pancreatic β-cells. MB05032 increases neutrophil adhesion, phagocytosis, and mRNA abundance of HKII, ITGA9, CD36 in subclinically hypocalcemic dairy cows. MB05032 inhibits gluconeogenesis in hepatocytes, acts as the active metabolite of prodrug Managlinat dialanetil (MB06322) (HY-14955). MB05032 can be used for the research of gastric cancer, type 2 diabetes, subclinical hypocalcemia, and insulin resistance .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-111431
CAS No.: 3233-58-7
Purity:  99.87%
Synonyms: p-Tolyl sulfate
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-19369
CAS No.: 292632-98-5
Synonyms: L-685,458
Target:  

γ-secretase Apoptosis

Research Areas:  

Neurological Disease Cancer

L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0366A
CAS No.: 969-33-5
Synonyms: Cyproheptadine HCl
Cyproheptadine hydrochloride (Cyproheptadine HCl) acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine hydrochloride mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine hydrochloride induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine hydrochloride inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine hydrochloride can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B1622
CAS No.: 129-03-3
Cyproheptadine acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B1165
CAS No.: 41354-29-4
Cyproheptadine hydrochloride sesquihydrate acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine hydrochloride sesquihydrate mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine hydrochloride sesquihydrate induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine hydrochloride sesquihydrate inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine hydrochloride sesquihydrate can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-103038
CAS No.: 1883510-31-3
Purity:  98.06%
Target:  

c-Myc Autophagy

Research Areas:  

Cancer

ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-131370B
CAS No.: 68890-65-3
Synonyms: 20% Fat Emulsion
Intralipid 20% is a safe fat emulsion, composed of soybean oil (consisting of a mixture of long-chain triglycerides (C14-24) of predominantly unsaturated fatty acids), and egg phospholipids, can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-103473
CAS No.: 67247-12-5
Purity:  99.93%
Synonyms: Boc-Met-Leu-Phe-OH
Research Areas:  

Inflammation/Immunology

Boc-MLF (Boc-Met-Leu-Phe-OH) is a competitive FPR1 antagonist. Boc-MLF inhibits fMLF-induced neutrophil activation through FPR. Boc-MLF inhibits receptor-induced inflammation and cell migration. Boc-MLF inhibits amniotic epithelial-mesenchymal transition. Boc-MLF reduces pro-inflammatory cytokine levels. Boc-MLF increases collagen expression in fetal membranes. Boc-MLF reverses fetal membrane epithelial cell collapse, increases villi, and reduces mucus attachment. Boc-MLF can be used in research on premature rupture of fetal membranes .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-103473A
Purity:  99.48%
Synonyms: Boc-Met-Leu-Phe-OH TFA
Research Areas:  

Inflammation/Immunology

Boc-MLF TFA (Boc-Met-Leu-Phe-OH TFA) is a competitive FPR1 antagonist. Boc-MLF TFA inhibits fMLF-induced neutrophil activation through FPR. Boc-MLF TFA inhibits receptor-induced inflammation and cell migration. Boc-MLF TFA inhibits amniotic epithelial-mesenchymal transition. Boc-MLF TFA reduces pro-inflammatory cytokine levels. Boc-MLF TFA increases collagen expression in fetal membranes. Boc-MLF TFA reverses fetal membrane epithelial cell collapse, increases villi, and reduces mucus attachment. Boc-MLF TFA can be used in research on premature rupture of fetal membranes .
loading...
    loading...